Company profile: NeuroReality
1.1 - Company Overview
Company description
- Provider of VR-based cognitive rehabilitation and brain training solutions using neuroscience and gamification. Offers Koji's Quest, a patient-centric SaaS VR game for recovery from brain injuries, connecting clinicians and patients to improve outcomes and enable superior care. Organizes clinical trials to evaluate effectiveness and prepares Koji's Quest for individual self-training via the Oculus Quest store.
Products and services
- Clinical Trials: NeuroReality architects evidence-based clinical trials evaluating Koji's Quest’s effectiveness in cognitive rehabilitation for various brain injuries, producing data for clinicians and stakeholders
- Koji's Quest: A SAAS game that engineers patient-centered VR cognitive rehabilitation using neuroscience and gamification, aiding recovery from various brain injuries and connecting stakeholders for better outcomes and scalable clinician care, VR-based
- Self-Training: NeuroReality offers individual self-training with Koji's Quest for cognitive rehabilitation, prepared for release on the Oculus Quest store for recovery from various brain injuries, Oculus Quest-compatible
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeuroReality
Cervel Neurotech
HQ: United States
Website
- Description: Provider of medical device solutions for non-invasive deep brain neuro-modulation, pioneering an innovative, proprietary approach based on repetitive transcranial magnetic stimulation (rTMS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cervel Neurotech company profile →
Convergence Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of novel analgesics for the treatment of chronic pain. An independent biotechnology company focused on developing therapies with potentially commercially attractive efficacy, responder-rate, and side effect profiles. Formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (GSK).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Convergence Pharmaceuticals company profile →
Landos Biopharma
HQ: United States
Website
- Description: Provider of oral, first-in-class, locally acting small-molecule therapeutics for autoimmune diseases. Pipeline: NX-13 (NLRX1) for ulcerative colitis and Crohn’s; LABP-66 (NLRX1) for multiple sclerosis and neurodegenerative disorders; LABP-73 (NLRX1) for asthma and eosinophilic disorders; LABP-69 (PLXDC2) for rheumatoid arthritis, ulcerative colitis, and Crohn’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Landos Biopharma company profile →
JuvLabs
HQ: Isle of Man
Website
- Description: Provider of biotech therapies and products to modify aging and address age-related diseases. Through its JuvRx therapeutics division, the company develops novel treatments targeting fibrosis and inflammatory conditions, including serpin-based PAI-1 inhibitors, TGF-β modulation drugs, NAD+ metabolism enhancers (with the Buck Institute), ketone-based therapies for heart failure, and an oral plasmalogen precursor to restore cell function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JuvLabs company profile →
Proximagen
HQ: United Kingdom
Website
- Description: Provider of neuroscience research and drug development targeting neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease; publicly traded.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proximagen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeuroReality
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeuroReality
2.2 - Growth funds investing in similar companies to NeuroReality
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeuroReality
4.2 - Public trading comparable groups for NeuroReality
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →